1 obulin M levels and incidence of symptomatic hyperviscosity.

2  microcytosis and exacerbate the symptoms of hyperviscosity.

3 y low hematocrit for SCD patients because of hyperviscosity.

4 should be used for patients with symptomatic hyperviscosity and before rituximab for those with high

5 heresis should be considered for symptomatic hyperviscosity and for prophylaxis in patients in whom r

6 tion, cytopenias, IgM-related complications, hyperviscosity, and neuropathy).

7 gan damage (anemia, constitutional symptoms, hyperviscosity, lymphadenopathy, or hepatosplenomegaly).

8 ulky adenopathy or organomegaly, symptomatic hyperviscosity, peripheral neuropathy, amyloidosis, cryo

9  adenopathy and/or organomegaly, symptomatic hyperviscosity, peripheral neuropathy, amyloidosis, cryo

10  promptly initiated before cytoreduction for hyperviscosity-related symptoms.

11 etachments were not associated with signs of hyperviscosity retinopathy in 5 eyes and resolved after

12  immunoglobulin M (IgM), which can lead to a hyperviscosity syndrome (HVS) and HVS-related retinopath

13           The latter is likely the result of hyperviscosity syndrome and volume overload, although a

14 tomatic disease requiring therapy, including hyperviscosity syndrome in those patients with MYD88(L26

15 collected from patients with the symptoms of hyperviscosity syndrome were tested on the nanoliter cap

16  in high-risk groups, including polycythemia-hyperviscosity syndrome, hypertension, and vascular thro

17 clonal protein will lead to a characteristic hyperviscosity syndrome.

18 vents, cerebrovascular complications, or the hyperviscosity syndrome.